CytomX Therapeutics (CTMX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

CytomX Therapeutics

NasdaqGS•Healthcare•Biotechnology

$2.77+0.08(0.03%)After hours

Market Cap

$588.95M

P/S

32.2x

P/B

1.9x

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.

How this company scores

WeakMetricSide Score: 21/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (0/25).

Profitability0/25

Growth0/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 19.0x5y range 1.3x – 19.0x

Currently above its 7-quarter median.

P/S · 32.2x5y range 0.4x – 32.2x

Currently above its 20-quarter median.

P/B · 1.9x5y range 1.9x – 5.8x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 6693.9% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $588.95M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $18.30M
Q. Revenue: $1.42M
TTM EBITDA: $-85.95M
TTM Op. Income: $-87.15M
Q. Op. Income: $-23.78M
TTM Net Income: $-79.65M
Q. Net Income: $-20.67M
EPS: $-0.09
Shares Out.: $218.94M

$18.30M in TTM revenue declined 87.0% YoY, reaching $1.42M last quarter. TTM EBITDA of $-85.95M and TTM operating income of $-87.15M show growth is flowing through to the bottom line. However, net income is negative at $79.65M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 5 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -1677.1%
Op. Margin: -1677.1%
Net Margin: -1457.4%

Op. margin of -1677.1% is down 1670.2% YoY — costs are rising relative to revenue. Net margin at -1457.4% Over the past year, operating margin is down 24232% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 32.2x
P/B Ratio: 1.9x

P/S of 32.2x and P/B of 1.9x. P/S is high, meaning growth expectations are priced in. Across the last 5 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $381.23M
Cash: $17.22M
Long-Term Debt: N/A
Book Value: $302.07M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-18.07M
TTM Free Cash Flow: $-82.48M
FCF Margin: -450.7%
FCF / Net Income: 1.0

TTM FCF of $-82.48M on $-18.07M in operating cash flow. The FCF / Net Income ratio of 1.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 3 consecutive quarters — a weakening trend.